Skip to content
Evigrade
CriticalSelective If channel inhibitor of the sinoatrial node×Systemic antimycotics. Imidazole derivatives

Updated · Methodology

Mechanism

In the liver and gut, only the enzyme CYP3A4 breaks down ivabradine, and ketoconazole strongly inhibits this enzyme and the transporter P-glycoprotein (ivabradine and ketoconazole summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Ketoconazole 200 mg once daily, like josamycin, raised mean ivabradine plasma exposure 7- to 8-fold, and high ivabradine levels can cause excessive slowing of the heart rate (ivabradine SmPC, EMA). In Cushing's syndrome ketoconazole is given at 400–1200 mg a day, and its European SmPC says that a stronger interaction can be expected at higher doses and shorter dosing intervals (ketoconazole SmPC, EMA). The second mechanism involves the QT interval: ketoconazole itself can prolong QT, and the slower heart rate caused by ivabradine can worsen QT prolongation (ketoconazole label, US Food and Drug Administration, FDA; ivabradine SmPC, EMA).

Symptoms

Excess ivabradine causes severe and prolonged slowing of the heart rate: a resting heart rate below 50 beats per minute, dizziness, fatigue and low blood pressure. With ivabradine, luminous phenomena in the visual field (phosphenes) and bradycardia are dose-dependent (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Sinus arrest and heart block have occurred during ivabradine treatment (ivabradine label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ketoconazole 200 mg twice daily for 3–7 days increased the heart-rate-corrected QT interval by a mean maximum of about 6–12 ms (ketoconazole FDA label). A slow heart rate may increase the risk of QT prolongation and severe ventricular arrhythmias, including torsade de pointes (ivabradine FDA label).

Management

The combination is contraindicated. The European ivabradine summary of product characteristics (SmPC) lists ketoconazole among the strong inhibitors of the enzyme CYP3A4 that must not be taken with ivabradine (ivabradine SmPC, European Medicines Agency, EMA). The US label contraindicates all strong CYP3A4 inhibitors, giving azole antifungals as an example (ivabradine label, US Food and Drug Administration, FDA). The European ketoconazole SmPC does not name ivabradine, but it warns that its list of contraindicated combinations is not complete. When starting ketoconazole, check the SmPC of each concomitant medicine for advice on use with strong CYP3A4 inhibitors (ketoconazole SmPC, EMA). In the European Union, oral ketoconazole is used for endogenous Cushing's syndrome, and doctors experienced in endocrinology or internal medicine start and supervise treatment (ketoconazole SmPC, EMA). If ketoconazole is needed, pause ivabradine for the duration of treatment (this follows from the contraindication). Ketoconazole is contraindicated in documented prolongation of the heart-rate-corrected QT interval (QTc). Record an electrocardiogram (ECG) before treatment, within the first week and then as clinically indicated. With QTc-prolonging drugs, the SmPC recommends ECG monitoring (ketoconazole SmPC, EMA). The contraindication applies to oral ketoconazole. No measurable plasma ketoconazole was found after the cream was applied to adult skin or the gel to the scalp. It was found after the cream was applied to a large skin area in infants and after the gel was applied to the whole body. No interaction studies have been done with the cream or gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). If the drugs have already been taken together, stop one of them (this follows from the contraindication) and monitor the heart rate and ECG. With a resting heart rate below 50 beats per minute or symptoms of bradycardia, reduce the ivabradine dose, and if bradycardia persists, stop ivabradine (ivabradine SmPC, EMA). Treat severe bradycardia in a specialised setting: if it is poorly tolerated, consider intravenous beta-stimulants such as isoprenaline and, if needed, temporary cardiac pacing (ivabradine SmPC, EMA). The documents give no interval for restarting ivabradine after ketoconazole is stopped. Before restarting, measure the resting heart rate several times by ECG or 24-hour monitoring, and do not start ivabradine if it is below 70 beats per minute (ivabradine SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ivabradine

Other interactions with Ketoconazole